wang shusen: Clinical Trials

6 trials sponsored by wang shusen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown, 1 recruiting, 1 suspended. 4 Phase 2, 1 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Unknown 2, Recruiting 1, Suspended 1
Not applicable1Unknown 1
Phase 31Unknown 1

Follow wang shusen: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Trilaciclib, Epirubicin, Cyclophosphamide - Breast Neoplasms
Phase 2Recruitingwang shusen1162023-09-202023-11-30
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Fluzoparib, Fluzoparib+Camrelizumab - Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
Phase 2Suspendedwang shusen802022-11-232026-03-17
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Tucidinostat, Capecitabine, Endocrine Therapy - Breast Cancer
Phase 2Unknownwang shusen732022-10-032022-11-04
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial
Capecitabine, Tucidinostat - Triple Negative Breast Cancer
Phase 2Unknownwang shusen1262022-08-012022-11-04
PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
prophylactic cranial irradiation - Breast Cancer, Brain Metastasis
Not applicableUnknownwang shusen3262017-08-012017-06-01
The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia
PEG-rhG-CSF - Breast Cancer
Phase 3Unknownwang shusen3382016-05-042017-06-01

Conditions studied

Breast Neoplasms (4)  ·  Triple Negative Breast Neoplasms (2)  ·  Brain Neoplasms (1)

Interventions

Capecitabine (2)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2)  ·  Anastrozole (1)  ·  Carboplatin (1)  ·  Cyclophosphamide (1)  ·  Docetaxel (1)  ·  Epirubicin (1)  ·  Fulvestrant (1)  ·  Letrozole (1)  ·  Paclitaxel (1)  ·  Trastuzumab (1)  ·  exemestane (1)  ·  fluzoparib (1)  ·  pegylated granulocyte colony-stimulating factor (1)  ·  pertuzumab (1)

Countries

China (6)

Top investigators

Susen Wang, MD (2)  ·  Shusen Wang (1)  ·  Shusen Wang, Doctor (1)  ·  Shusen Wang, MD (1)